arrow
H

Howard Feldman

university of wisconsin madison
H指数:104
被引数:8.9万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Protocol for the Asian Cohort for Alzheimer's Disease (ACAD) Study
2025-12-220
OAAI
Varoglutamstat improves eGFR and offers a new approach to treat diabetic kidney disease (DKD): meta-analysis from two independent phase 2 studies

Varoglutamstat改善eGFR,为治疗糖尿病肾病(DKD)提供了一种新方法:两项独立II期研究的荟萃分析

2025-10-010
PRE
Tailoring implementation strategies for the healthy actions and lifestyles to Avoid Dementia or Hispanos y el ALTo a la Demencia Program: Lessons learned from a survey study

为“避免痴呆或Hispanos y el ALTo a la Demencia项目”量身定制实施策略,以促进健康行为和生活方式:来自一项调查研究的经验教训

2025-03-010
OAAI
evoke and evoke plus : design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomatic Alzheimer's disease

evoke和evoke plus: 两项大规模,双盲,安慰剂对照的3期研究的设计,评估了semaglutide在早期症状性阿尔茨海默氏病中的疗效,安全性和耐受性

2025-01-081
OAAI
Impact of a national dementia research consortium: The Canadian Consortium on Neurodegeneration in Aging (CCNA)

国家痴呆症研究联盟的影响: 加拿大衰老神经变性联盟 (CCNA)

2024-12-051
PRE
Post hoc analysis of ADAMANT, a phase 2 clinical trial of active tau immunotherapy with AADvac1 in patients with Alzheimer's disease, positive for plasma p-tau217

ADAMANT的事后分析,一项针对血浆p-tau217阳性的阿尔茨海默病患者的AADvac1主动tau免疫治疗的2期临床试验

2024-11-231
OAAI
Varoglutamstat: Inhibiting Glutaminyl Cyclase as a Novel Target of Therapy in Early Alzheimer's Disease
2024-10-181
OAAI
A framework for translating tauopathy therapeutics: Drug discovery to clinical trials
2024-09-241
OA